The effectiveness of tacrolimus and cyclosporine A after renal transplantation: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 5, Issue 3, 2005, Pages

  Li, Xu Dong ^a   Wu, Tai Xiang ^a   Su, Bin ^a   Yang, Yu Ru ^a   Li, Ya ^a   Wang, Li ^a   Lu, Yi Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cyclosporine A; Meta analyses; Renal transplantation; Systematic review; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; FK 506 BINDING PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; BIBLIOGRAPHIC DATABASE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; COCHRANE LIBRARY; COMPUTER PROGRAM; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; EMBASE; EVALUATION; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METHODOLOGY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 20044396165     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D. A three-arm study comparing immediate tacrolimus therapy with Antithymocyte globulin induction therapy followed by Tacrolimus or Cyclospoine A in adult Renal transplant recipients[J]. Transplantation, 2003; 75(6): 844-851.
2. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentrestudy[J]. Lancet, 2002; 359(9 308): 741-746.
3. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes D, Ehrich JH, Klare B, Zacchello G, Bjorn Brekke I, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, Stolpe J. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation[J]. Pediatr Nephrol, 2002; 17(3): 141-149.
4. White SA, Jain S, Williams ST, Doughman T, Hayes P, Murphy G, Veitch PS, Horsburgh T. Randomized trial comparing neoral and tacrolimus immunousuppression for recipients of renal transplants procured from different donor groups[J]. Transplant Proc, 2000; 32(3): 600.
5. Xu D, Tang XD. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation[J]. Transplant Proc, 2000; 32(3): 1 702-1 703.
6. Campos HH, Abbud Filho M, Brazilian Tacrolimus Study Group. One-year follow-up of a Brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation[J]. Transplant Proc, 2002; 34(5): 1 656-1 658.
7. Abou-Jaoude MM, Irani-Hakime N, Ghantous I, Najm R, Afif C, Almawi WY. Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients[J]. Transplant Proc, 2003; 35(7): 2 748-2 749.
8. Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Leonhardt M, Fitzsimmons WE. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years[J]. Transplantation, 2003; 75(12): 2048-2053.
9. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and Cyclosporine in kidney transplantation: evidence for improved allograft survival at five years[J]. Transplantation, 2002; 73(5): 775-782.
10. Montagnino G, Kramer BK, Arias M. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up [J]. Transplant Proc, 2002; 34(5): 1 635 -1 637.
11. Toz H, Sen S, Sezis M, Duman S, Ozkahya M, Ozbek S, Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies[J]. Transplant Proc, 2004; 36(1): 134-136.
12. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation[J]. Transplantation, 1997; 63(7): 977-983.
13. Wang XH, Tang XD. The prospective randomize study on prevention of cadaveric renal allograft rejection by Tacrolimus (FK506) [J]. Chin J Organ Transpant, 2000; 21(2): 117-118.
14. Yu LX, Liu XY, Sun XY, Du CF, Fu SJ, Xu J. Long-term evaluation of FK506 based immunosuppressive therapy in kidney transplantation[J]. Chin J Organ Transpant, 2003; 24(6): 361-363.
15. Mayer AD. Four-year follow-up of the European Tacrolimus Multicenter Renal Study[J]. Transplant Proc, 1999; 31(7A): 27S-28S.
16. Vincenti F. Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U. S. multicenter, randomized, comparative trial [J]. Transplant Proc, 2001; 33(1-2): 1 019-1 020.
17. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial [J]. Transplant Proc, 1998; 30(4): 1 216-1 218.
18. Yu L, Wang Y, Fu SJ, Cheng XJ. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation [J]. Transplant Proc, 2000; 32(7): 1 709-1 710.
19. Ferguson R. Acute rejection episodes: Best predictor of long-term primary cadaveric renal transplant survival[J]. Clin Transplant, 1994; 8 (3 Pt 2): 328-331.
20. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival[J]. Transplantation, 1995; 60(12): 1 384-1 384.
21. US Renal Transplantation Mycophenolate Mofetil Study Group. Mycophenolate Mofetil in cadaveric renal transplantation[J]. Am J kidney Diease, 1999; 34(2): 296-303.